Teva Pharmaceuticals Unit Actavis Generics Wins FDA Approval for Lung Cancer Drug Pemetrexed

Teva Pharmaceuticals (NYSE: TEVA) has a new treatment it can market. The company's Actavis Generics unit has been granted Food and Drug Administration (FDA) approval for its Pemetrexed chemotherapy treatment, which combats lung cancer.

An injectable form of the drug has been approved as a single agent for use in patients with "locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has not progressed after four cycles of first-line platinum-based chemo[therapy]."

Image source: Getty Images.

Source Fool.com